177 related articles for article (PubMed ID: 34429238)
1. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study.
Moriarty F; Larkin J; Fahey T
Health Policy; 2021 Oct; 125(10):1297-1304. PubMed ID: 34429238
[TBL] [Abstract][Full Text] [Related]
2. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
Mulinari S; Ozieranski P
BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
[TBL] [Abstract][Full Text] [Related]
3. Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016.
Stoll M; Hubenschmid L; Koch C; Lieb K
BMJ Open; 2020 Sep; 10(9):e037395. PubMed ID: 32948560
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
5. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).
Ozieranski P; Csanádi M; Rickard E; Mulinari S
BMJ Open; 2020 Sep; 10(9):e037351. PubMed ID: 32950962
[TBL] [Abstract][Full Text] [Related]
6. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
8. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
[TBL] [Abstract][Full Text] [Related]
9. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.
Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A
Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries.
Mulinari S; Martinon L; Jachiet PA; Ozieranski P
Health Policy; 2021 Jul; 125(7):915-922. PubMed ID: 34006392
[TBL] [Abstract][Full Text] [Related]
11. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
[TBL] [Abstract][Full Text] [Related]
12. Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.
Rickard E; Carmel E; Ozieranski P
BMJ Open; 2023 Mar; 13(3):e061591. PubMed ID: 36990486
[TBL] [Abstract][Full Text] [Related]
13. Health Services and Policy Research in Canada: An Editor's Reflections.
Lexchin J
Healthc Policy; 2022 Feb; 17(3):42-48. PubMed ID: 35319443
[TBL] [Abstract][Full Text] [Related]
14. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.
Parker L; Karanges EA; Bero L
BMJ Open; 2019 Feb; 9(2):e024928. PubMed ID: 30782921
[TBL] [Abstract][Full Text] [Related]
15. Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.
Sawano T; Ozaki A; Saito H; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 May; 2(5):e193817. PubMed ID: 31099864
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota.
Ross JS; Lackner JE; Lurie P; Gross CP; Wolfe S; Krumholz HM
JAMA; 2007 Mar; 297(11):1216-23. PubMed ID: 17374816
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study.
Norris SL; Holmer HK; Ogden LA; Burda BU; Fu R
BMC Med Ethics; 2012 Sep; 13():24. PubMed ID: 23013260
[TBL] [Abstract][Full Text] [Related]
19. Physicians' attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey.
Stoll M; Hubenschmid L; Koch C; Lieb K; Egloff B
BMJ Open; 2022 Jun; 12(6):e055963. PubMed ID: 35750457
[TBL] [Abstract][Full Text] [Related]
20. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan.
Yamamoto K; Murayama A; Ozaki A; Saito H; Sawano T; Tanimoto T
Int Urogynecol J; 2021 Feb; 32(2):443-451. PubMed ID: 33151353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
